Key Event Components

Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
A complete list of all KECs is available in TSV format on the Downloads Page.

Showing 1001 to 1025 of 1141 KECs

ID	Action	Process	Object	Associated Key Events (KEs)


141	abnormal	reproductive behavior (GO:0019098)		363: Altered, Reproductive behaviour
140	increased	Kidney Diseases (MESH:D007674)		252: Increase, Renal pathology due to VTG deposition
139	increased	gene expression (GO:0010467)	vitellogenins (MESH:D014819)	2 Events 307: Increase, Vitellogenin synthesis in liver 418: Increased, Vitellogenin synthesis
138	increased		vitellogenins (MESH:D014819)	2 Events 220: Increase, Plasma vitellogenin concentrations 419: Increased, renal vitellogenin deposition
137	increased	estrogen receptor activity (GO:0030284)	estrogen receptor (PR:000007204)	3 Events 111: Agonism, Estrogen receptor 659: Decreased testosterone by the fetal Leydig cells, Activation by other estradiol agonists 748: Increased, Estrogen receptor (ER) activity
136	abnormal	multi-organism reproductive process (GO:0044703)		253: N/A, Reproductive failure
135	functional change		eggshell (UBERON:0005079)	119: N/A, Gap
134	decreased		eggshell (UBERON:0005079)	106: Reduction, Eggshell thickness
133	decreased	bicarbonate transport (GO:0015701)	hydrogencarbonate (CHEBI:17544)	49: Reduction, Ca and HCO3 transport to shell gland
132	decreased		prostaglandin E2 (CHEBI:15551)	2 Events 243: Reduction, Prostaglandin E2 concentration 687: Reduced, Prostaglandin E2 concentration, hypothalamus
131	decreased	prostaglandin-endoperoxide synthase activity (GO:0004666)	prostaglandin G/H synthase 2 (PR:000013428)	79: Inhibition, Cyclooxygenase activity
130	decreased	prostaglandin-endoperoxide synthase activity (GO:0004666)	prostaglandin G/H synthase 1 (PR:000013427)	2 Events 79: Inhibition, Cyclooxygenase activity 1103: Inhibition, Cyclooxygenase 1 activity
129	occurrence		cholestasis (MESH:D002779)	2 Events 357: Cholestasis, Pathology 1059: Increased, cholestasis
128	increased	inflammatory response (GO:0006954)		5 Events 149: Increase, Inflammation 901: Infiltration, Inflammatory cells 1087: Increased, inflammation 1225: Immune system inflammation 2097: Increase, Pro-Inflammatory Mediators
127	increased	cytokine secretion (GO:0050663)	Cytokine (FMA:84050)	87: Release, Cytokine
126	increased		bile (UBERON:0001970)	214: Bile accumulation, Pathological condition
125	increased	gene expression (GO:0010467)	bile acid receptor (PR:000011396)	288: Activation of specific nuclear receptors, Transcriptional change
124	decreased	transport (GO:0006810)	bile salt export pump (PR:000003549)	41: Inhibition, Bile Salt Export Pump (ABCB11)
123	increased	oxidative stress (MP:0003674)		3 Events 209: Peptide Oxidation 1279: Increase, Oxidative Stress / Activation, PMK-1 P38 MAPK 1392: Increase, Oxidative Stress
122	decreased	long-term synaptic potentiation (GO:0060291)		166: Decreased, Long-term potentiation (LTP)
121	decreased		nitric oxide (CHEBI:16480)	193: Decreased, Nitric Oxide
120	increased	reactive oxygen species biosynthetic process (GO:1903409)	reactive oxygen species (CHEBI:26523)	1115: Increase, Reactive oxygen species
119	decreased	ATP biosynthetic process (GO:0006754)	ATP (CHEBI:15422)	4 Events 40: Mitochondrial ATP production, decreased 1138: Uncoupling of oxidative phosphorylation, Reduced ability to generate ATP 1771: Decrease, Adenosine triphosphate pool 1472: Decrease, ATP production
118	disrupted		mitochondrial respiratory chain (GO:0005746)	178: Mitochondrial electron transport chain, disrupted
117	increased		calcium ion (CHEBI:39124)	50: Increase, Ca++ (intracellular)